- Assistant Professor of Oncology
- Assistant Professor of Urology
Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.
Cell-based therapeutics and the tumor microenvironment. ...read more
Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 2016 Jun; 91: 140-50. PMID: 27019026.
Brennen WN, Rosen DM, John T. Isaacs, Denmeade SR. Targeting carcinoma associated fibroblasts within the reactive stroma with a fibroblast activation protein (FAP)-activated prodrug. JNCI. 2012, Sept 5; 104(17): 1320-34. PMID: 22911669.
Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 2013 Jan; 4(1): 106-17. PMID: 23362217.
Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell Armamentarium as a Cell-based Therapy for Prostate Cancer. Cancer Res. 2014 Jul 1; 74(13): 3390-5. PMID: 24747912.
Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013 Aug 23; 20(5): R269-90. PMID: 23975882.